Considers S. 1552 and companion H.R. 6245, the Drug Industry Antitrust Act, to amend the Federal Food, Drug, and Cosmetic Act and Sherman Antitrust Act to establish drug company licensing procedures, to require FDA to certify the effectiveness of all new drugs, to require advertisements sent to physicians to contain FDA warnings on the drug, and to limit drug company rights to exclusive production of patented drugs.

Reviews cooperative efforts among Federal and international agencies responsible for medical research on experimental drugs and regulation of pharmaceutical industry marketing practices. Includes review of thalidomide marketing and use.

Reviews cooperative efforts among Federal and international agencies responsible for medical research on experimental drugs and regulation of pharmaceutical industry marketing practices. Includes review of thalidomide marketing and use, drugs for mental illness, neonatal pharmacology, etc.